Background. We investigated the patterns and predictors for virological relapse (VR), clinical relapse (CR), and sustained clinical response (SCR) and the outcomes of retreatment after nucleos(t)ide analogue (NUC) therapy discontinuation.
Hepatitis B virus (HBV) surface antigen (HBsAg) seroconversion defines functional cure for chronic hepatitis B [1] . Lifelong therapy is usually necessary because achieving seroconversion requires decades [2] . However, in resource-constrained regions, nucleos(t)ide analogue (NUC) therapy of finite duration is common. The long-term safety of NUC therapy is a growing concern about the risk of lactic acidosis and threats to renal and bone safety [3] . In addition, poor adherence to long-term NUC therapy can lead to viral breakthrough or genotypic resistance [4] .
Identification of candidates for NUC therapy discontinuation that yield sustained viral suppression and the lowest likelihood of relapse remains an unmet clinical need. Several predictors for virological relapse (VR) or clinical relapse (CR) have been reported, including baseline viral factors (eg, HBV load and genotype) [5] [6] [7] , treatment-associated factors (eg, treatment and consolidation duration) [5, 8, 9] , and end-oftherapy (EOT) factors (eg, HBsAg level) [6] . Liver injury during chronic hepatitis B is caused by the host's immune response against HBV. Therefore, immunity-related host factors may be crucial for relapse prediction. The serum anti-HBV core antibody (anti-HBc) level has been considered a serological factor reflecting the host's immune status and hepatitis activities [10] . Sodium taurocholate cotransporting polypeptide (NTCP) was identified as an entry receptor for HBV. The S267F variant (c.800G>A; rs2296651) has been associated with resistance to HBV infection and reported to reduce the risk of disease progression [11, 12] . High levels of viral antigens have been associated with T-cell exhaustion in patients with chronic hepatitis B [13] . A study reported that after long-term NUC therapy, HBV-specific CD8 + T-cell functions could be partly restored [14] . Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) is an inhibitory T-cell receptor that regulates T-cell activation and T-helper type 1 (Th1)/Th2 cytokine production, and it is associated with T-cell exhaustion. The +49 G allele of the rs231775 single-nucleotide polymorphism (SNP) site in CTLA4 is associated with HBV clearance [15] . HLA-DP is an HLA class II molecule, presenting antigens to CD4 + T cells. The HLA-DP locus is strongly associated with persistent HBV infection [16, 17] . The A alleles of rs3077 (in the 3′ untranslated region of the gene encoding HLA-DPA1) and rs9277535 (in the 3′ untranslated region of the gene encoding HLA-DPB1) were found to protect against HBV persistence [16] . Knowledge regarding whether these host factors are associated with HBV relapse after discontinuation of NUC therapy is limited. Thus, we conducted this study to determine the patterns and predictors of relapse and the outcomes after NUC therapy discontinuation.
METHODS

Patients
We conducted this prospective cohort study by consecutively enrolling and following up noncirrhotic patients with chronic hepatitis B who discontinued NUC therapy at the National Taiwan University Hospital between October 2012 and August 2017. According to the National Health Insurance reimbursement guidelines in Taiwan, NUC therapy can be reimbursed for 3 years for patients with chronic hepatitis B who fulfill the Asian Pacific Association for the Study of the Liver (APASL) guidelines [18] . Patients with cirrhosis, human immunodeficiency virus coinfection, hepatitis C virus coinfection, autoimmune hepatitis, or chronic alcoholism were excluded.
The therapeutic end point was defined as a combination of HBV e antigen (HBeAg) loss or seroconversion, an undetectable serum HBV DNA level for >12 months in HBeAg-positive patients, and an undetectable serum HBV DNA level for >12 months in HBeAg-negative patients, according to the APASL rules for stopping therapy [18] . Consolidation therapy was defined as treatment after the first report of undetectable HBV DNA (and HBeAg loss, for HBeAg-positive patients) and lasted until cessation of NUC treatment [8] .
After the discontinuation of NUC therapy, patients were followed up at 1 and 3 months and every 3 months thereafter for 2 years for assessment of alanine aminotransferase (ALT) and HBV DNA levels. VR was defined as an HBV DNA level of >2000 IU/mL [18] . CR was defined as VR with a 2-fold elevation of ALT level from the upper limit of normal (ie, <41 IU/mL). Sustained clinical response (SCR) was defined as an HBV DNA level of <2000 IU/mL with a normal ALT level 12 months after cessation of therapy. During the ALT level flare, the physician shortened the follow-up interval to every 1-2 weeks, for close monitoring and identification of signs of decompensation. The timing of retreatment was based on the physician's clinical judgment. Retreatment was reimbursed if ALT levels were elevated by >2-fold for 3 months along with an HBV DNA level of >2000 IU/mL or if signs of liver decompensation (ie, a total bilirubin level of >2mg/dL or a prolongation of the prothrombin time by 3 seconds) were observed. The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of National Taiwan University Hospital. All patients provided written informed consent before enrollment.
Virological and Serological Tests
Serum HBV DNA levels were measured using the Abbott RealTime HBV assay (Abbott Laboratories, Abbott Park, IL) with a lower detection limit of 20 IU/mL. Serum HBsAg titers were quantified using the Architect HBsAg QT assay (Abbott) with a diagnostic range of 0.05-250 IU/mL. Serial 1:100 to 1:1000 dilutions were performed if the HBsAg level was >250 IU/mL. The serum anti-HBc level was measured using a double-sandwich immunoassay (Wantai, Beijing, China; dynamic range, 0.08-2.5 IU/mL). The samples were tested at dilutions of 1:10 to 1:100000 (a 10-fold increase) if the anti-HBc level was >2.5 IU/mL [10] .
Determination of the SNPs
Genomic DNA was extracted from peripheral blood mononuclear cells by using QIAamp kits (Qiagen, Valencia, CA). The SNPs of the NTCP (rs2296651), CTLA4 (rs231775), HLA-DPA1 (rs3077), and HLA-DPB1 (rs9277535) regions were genotyped using the ABI TaqMan allelic discrimination kit and the StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA) according to the manufacturers' protocols.
Statistical Analysis
The continuous variables are reported as median values (interquartile ranges), and categorical data are reported as numbers (percentages). The HBV DNA, HBsAg, and anti-HBc levels were logarithmically transformed for statistical analysis. Differences between groups were evaluated by the Student t test or the χ 2 test. The entry date was the day of EOT. The time at risk as a continuous variable was measured from the entry date until the development of VR, CR, the last hospital visit, or the time of retreatment, whichever came first. The cumulative incidence rates of VR and CR were estimated through KaplanMeier analyses and compared using the log-rank test. The risks of VR and CR were modeled using a Cox proportional hazards regression analysis, after adjustment for age, sex, and relevant parameters. Logistic regression analysis was used to predict the SCR 12 months after the cessation of therapy. The statistical analysis was performed using Stata (v13.0; Stata Corp, College Station, TX). All tests were 2-sided, and P values of < .05 were considered significant.
RESULTS
Overall, 172 patients with chronic hepatitis B who discontinued NUC therapy were prospectively enrolled. We excluded 57 patients who did not meet the APASL stopping criteria before NUC therapy discontinuation. Four and 11 patients who received adefovir, and telbivudine, respectively, were excluded because of small case numbers. Finally, we included 100 patients with chronic hepatitis B who discontinued treatment with entecavir (ETV; n = 66) and tenofovir disoproxil fumarate (TDF; n = 34).
All patients were HBeAg negative and had an HBV DNA level of <20 IU/mL for >12 months when treatment was discontinued. The median age was 51 years, and 72 patients (72%) were male ( Table 1 ). The median treatment and consolidation duration was 37 months and 26 months before EOT, respectively, fulfilling the current recommendation to discontinue NUC therapy [9, 19] . The median follow-up duration was 32 months in patients with CR and 35 months in patients without CR. No differences among the EOT ALT, HBV DNA, HBsAg, or anti-HBc levels were observed among patients receiving ETV or TDF therapy. All SNPs (rs2296651, rs231775, rs3077, and rs9277535) were in Hardy-Weinberg equilibrium.
Significant Earlier Relapse After Discontinuation of TDF Treatment
The relapse patterns of different NUCs are shown in Figure 1 . Patients who discontinued TDF therapy developed VR significantly more rapidly and to a significantly higher degree than did those who received ETV (log-rank P = .038). A majority of the patients who discontinued TDF therapy developed VR at 3 months after therapy, whereas patients in the ETV group developed VR after 3 months. In addition, patients who discontinued TDF therapy developed CR earlier than did those who discontinued ETV.
After EOT, the 3-and 6-month cumulative VR rates were significantly higher in the TDF group than the rates in the ETV group (52.9% vs 6.1% [P < .001] and 58.8% vs 33.3% [P = .014], respectively) ( Table 2 ). The median time to VR in the TDF group was significantly shorter than that in the ETV group (2.4 vs 6.2 months; P = .035). However, the 12-or 24-month cumulative VR rates were comparable between the TDF and ETV groups (65.2% vs 53.0% [P = .248] and 72.1% vs 65.2% [P = .142], respectively). In addition, the 3-month cumulative CR rates were significantly higher in the TDF group than in the ETV group (15.2% vs 1.5%; P = .007) However, the 6-, 12-, and 24-month cumulative CR rates were comparable between the TDF and ETV groups (27.3% vs 12.1% [P = .060], 30.6% vs 33.7% [P = .877], and 40.7% vs 46.1% [P = .664], respectively). In patients who were followed up for 24 months for VR or CR, the second-year relapse rate was significantly lower than the first-year relapse rate (24% vs 60% [P < .001] and 19% vs 36% [P = .031], respectively). The 12-month SCR rate was comparable between the patients who discontinued either TDF or ETV therapy (33.3% vs 45.5%; P = .248).
We further analyzed the relapse pattern according to baseline HBeAg status ( Figure 2 ). In patients who discontinued ETV a Single-nucleotide polymorphisms (SNPs) in genes encoding the receptors NTCP (rs2296651) and CTLA4 (rs231775) and in the 3′ untranslated regions of the genes encoding HLA-DPA1 (rs3077) and HLA-DPB1 (rs9277535). therapy, the cumulative incidence of VR (log-rank P = .274) and CR (log-rank P = .396) were comparable despite the differences in baseline HBeAg status. In patients who discontinued TDF therapy, the cumulative incidence rates of VR and CR were numerically lower in HBeAg-positive patients than in HBeAg-negative patients. Notably, the 12-month VR was significantly lower in HBeAg-positive patients than in HBeAgnegative patients (42% vs. 81%; P = .021) who discontinued TDF therapy, but this difference was not significant after adjustment for age.
Predictors for VR, CR, and SCR
In addition to identifying candidates for therapy cessation, we first investigated baseline factors (age, sex, HBeAg status, HBV genotype, prior therapy, and baseline ALT and HBV DNA levels), treatment-related factors (treatment or consolidation VR was defined as a hepatitis B virus (HBV) DNA level of >2000 IU/mL [18] . CR was defined as VR with a 2-fold elevation of the alanine aminotransferase (ALT) level from the upper limit of normal (ie, <41 IU/mL). Sustained clinical response (SCR) was defined as an HBV DNA level of <2000 IU/mL with a normal ALT level 12 months after cessation of therapy.
Abbreviations: CI, confidence interval; EOT, end of therapy. duration and NUC regimen or resistance), EOT factors (ALT and HBsAg levels), and host factors (anti-HBc levels and the SNPs rs2296651, rs231775, rs3077, and rs9277535) for prediction of VR and CR (Supplementary Table 1 Table 2) . We further investigated the predictors for SCR 12 months after cessation of NUC treatment, which indicates durability after NUC therapy discontinuation. After adjustment for age and sex, baseline HBeAg-positive status (odds ratio [OR], 6.42; 95% CI, 1.54-26.8; P = .011) and EOT HBsAg levels (OR, 0.57; 95% CI, .35-.94; P = .028) significantly predicted SCR. The HLA-DPA1 (rs3077) non-GG genotype tended to predict SCR (OR, 2.69; 95% CI, .68-10.6; P = 0.157), whereas the HLA-DPA1 (rs3077) AA genotype (as compared to the GG genotype) significantly predicted SCR (OR, 10.84; 95% CI, 1.12-105; P = .040; Supplementary Table 3) .
HBV DNA Level 1 Month After Therapy Predicted VR
Early posttherapy factors (eg, HBV DNA level 1 month after EOT and increases in ALT level) were included as early alarms or signals indicating relapse. In the model of posttherapy predictors, after adjustment for age, sex, HBsAg status, treatment regimen, and EOT HBsAg level, the HBV DNA level 1 month after therapy cessation significantly predicted VR (HR, 2.82; 95% CI, 2.06-3.85; P < .001) and CR (HR, 1.51; 95% CI, 1.12-2.03; P = 0.007) and negatively predicted SCR (OR, 0.26; 95% CI, .08-.80; P = .019). However, the increase in ALT level 1 month after therapy discontinuation did not predict subsequent VR, CR, or SCR (Table 4) .
Clinical Manifestation of VR and CR
Among the patients who discontinued ETV and TDF therapy, We found some patients only developed VR without subsequently CR and attempted to identify their characteristics. We excluded 5 patients who received retreatment at VR (who would not develop CR). The median time to VR was significantly longer in patients with VR only, compared with patients with both VR and CR (13.7 vs 5.1 months; P < .001) ( Table 5 ). Patients VR was defined as a hepatitis B virus (HBV) DNA level of >2000 IU/mL [18] . CR was defined as VR with a 2-fold elevation of the alanine aminotransferase (ALT) level from the upper limit of normal (ie, <41 IU/mL). SCR was defined as an HBV DNA level of <2000 IU/mL with a normal ALT level 12 months after cessation of therapy.
Abbreviations: anti-HBc, anti-hepatitis B virus core antigen; CI, confidence interval; EOT, end of therapy; ETV, entecavir; HBeAg, hepatitis B virus e antigen; HBsAg, hepatitis B virus surface antigen; HR, hazard ratio; OR, odds ratio; TDF, tenofovir disoproxil fumarate.
a Adjusted by age and sex.
b Per 1 log IU/mL increase.
c Single-nucleotide polymorphisms (SNPs) in genes encoding the receptors NTCP (rs2296651) and CTLA4 (rs231775) and in the 3′ untranslated regions of the genes encoding HLA-DPA1 (rs3077) and HLA-DPB1 (rs9277535).
without VR or CR had a significantly lower HBsAg level, compared with those who developed VR or CR (2.24 vs. 2.82 log IU/ mL; P < .001; Supplementary Table 4) .
NUC Retreatment and Outcome
From the entire cohort, 40 patients received retreatment, of whom 33 (83%) continued their original regimen. One patient who continued ETV therapy experienced drug resistance. The outcomes of patients who did and those did not receive retreatment and were followed up for >6 months are listed in Supplementary Table 5 .
All patients retreated for >6 months had an HBV DNA level of <100 IU/mL at the end of follow-up, except for 1 patient, who experienced relapse after completing another 3-year period of retreatment. Among another 7 patients who developed CR without retreatment, 86% continued to exhibit HBV DNA levels of >2000 IU/mL at the end of follow-up. In 20 patients who experienced VR only without retreatment, at the end of follow-up 80% exhibited a normal ALT level and 33% exhibited HBV DNA levels of <2000 IU/mL. Among 30 patients without VR or CR, 93% had normal ALT levels, and 58% had HBV DNA levels of <20 IU/mL.
DISCUSSION
The strengths of this study included a prospective study design, homogenous treatment course, and long follow-up after VR was defined as an HBV DNA level of >2000 IU/mL [18] . CR was defined as VR with a 2-fold elevation of the ALT level from the upper limit of normal (ie, <41 IU/mL). SCR was defined as an HBV DNA level of <2000 IU/mL with a normal ALT level 12 months after cessation of therapy.
Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; EOT, end of therapy; HBV, hepatitis B virus; HR, hazard ratio; OR, odds ratio.
a Adjusted by age, sex, HBV e antigen positivity, treatment regimen, and EOT HBV surface antigen level.
b Per 1 log IU/mL increase. Data are median values (interquartile ranges) or no. (%) of individuals. VR was defined as an HBV DNA level of >2000 IU/mL [18] . CR was defined as VR with a 2-fold elevation of the ALT level from the upper limit of normal (ie, <41 IU/mL).
Abbreviations: ALT, alanine aminotransferase; anti-HBc, anti-hepatitis B virus core antigen; EOT, end of therapy; ETV, entecavir; HBeAg, hepatitis B virus e antigen; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; TDF: tenofovir disoproxil fumarate.
treatment discontinuation. After a median treatment duration of 3 years and consolidation therapy duration of 2 years, the 1-year VR, CR, and SCR rates were 57%, 33%, and 34%, respectively. These results suggested that finite NUC therapy might be feasible in some patients. Notably, a distinct relapse pattern was observed after discontinuing TDF or ETV therapy. Similarly, the interim results from the FINITE-CHB trial had reported early relapse after long-term viral suppression in HBeAg-negative patients who received TDF therapy [20] . Even after a 7-year duration of TDF therapy with persistent viral suppression, 87.5% of patients infected with HBV genotype A or D were reported to experience VR between weeks 4 and 8 after discontinuation of TDF therapy [21] . In our patients, 52.9% (infected with HBV genotype B or C) experienced early VR within 3 months after TDF treatment discontinuation. Therefore, a NUC-specific monitoring protocol after therapy may be warranted. The first 3 months in particular are critical for VR or CR after the cessation of TDF. However, patients who discontinued ETV therapy should be monitored closely after 6 months. Despite the differences in relapse patterns, the 1-year overall relapse rates are comparable. The relapse rates (VR and CR) were significantly lower during the second year of follow-up than during the first year. The different mechanisms underlying the different relapse patterns between ETV and TDF discontinuation remain unclear. HBV viral replication can resume from residual covalently closed circular DNA (cccDNA) after treatment discontinuation [22] . The reduction of the cccDNA level after NUC therapy is insignificant, regardless of the potency of NUCs [23] ; therefore, the rapid relapse after discontinuation of TDF therapy is possibly not due to a relatively high level of residual cccDNA in infected hepatocytes. A recent study suggested that NUC therapy might have immunomodulatory capabilities. After 1 year of ETV therapy, the levels of both Th1 and Th2 cytokines increased, whereas the number of immunosuppressive Treg cells decreased with resultant immune activation [24] . By contrast, an in vitro study demonstrated that TDF reduced the release of inflammatory cytokines (interleukin 8 and CCL3) and shifted the interleukin 12/interleukin 10 balance after stimulation in human primary cells [25] . Therefore, the different relapse patterns may be due to distinct immunomodulatory effects of NUCs; however, additional studies are needed for confirmation.
We further investigated host immunological factors to predict relapse or sustained response and found that the CTLA4 (rs231775) non-GG genotype (AA+AG) was associated with VR and CR, whereas the HLA-DPA1 (rs3077) AA genotype was associated with SCR. CTLA4 is an inhibitory receptor expressed by T lymphocytes that acts largely as a negative regulator of T-cell responses. The CTLA4 (rs231775) A allele has been associated with a high risk of T-cell-mediated autoimmune diseases, infectious diseases, and carcinomas [26] . Our results were consistent with previous studies. The A allele of CTLA4 (rs231775) is associated with HBV persistence [15] and with disease progression and hepatocellular carcinoma [26, 27] . The antigen presentation on the HLA molecule is crucial for HBV elimination. The HLA-DP region was found to be associated with persistent HBV infection [16] , and, specifically, the A allele of HLA-DPA1 (rs3077) is associated with HBsAg seroclearance [28] . Our findings further extend the knowledge of CTLA4 (rs231775) and HLA-DPA1 (rs3077) in predicting the outcomes in patients with chronic hepatitis B after NUC therapy discontinuation. However, these findings should be validated by a larger cohort of patients.
Knowledge of the HBsAg level has been integrated into the management of chronic hepatitis B [29] [30] [31] . Previous studies have demonstrated controversial results on the value of EOT HBsAg levels for predicting relapse [5, 6, 32] . A recent systemic review suggested that an EOT HBsAg level of <200 IU/mL is predictive of subsequent relapse [19] . The EOT HBsAg level also facilitates prediction of the sustained viral response [33] . Our study confirms that a relatively low EOT HBsAg level is a reliable predictor for both VR and CR and serves as a possible discontinuing indicator, whereas the reappearance of HBV viremia within 1 month after therapy is a rapid predictor for relapse. These markers will enable practicing clinicians to select optimal candidates for NUC therapy discontinuation and stratify the risk of relapse or sustained response. No consensus exists for the posttherapy monitoring schedule based on the current guidelines [34] [35] [36] . The American Associated for the Study of Liver Diseases guideline suggests monitoring HBV DNA and ALT levels every 3 months after the EOT. Rapid VR after TDF treatment discontinuation in our study suggests that monitoring the HBV DNA levels in the first month after therapy cessation is necessary.
We observed that some patients developed VR only without CR during our follow-up. The exact reason why these patients only had VR but not CR was unclear, but we found that the VR-only patients developed VR significantly later than patients who developed both VR and CR. This finding may indicate that they have relatively robust immunological control after cessation of NUC therapy. In patients who developed CR, long-term virological control was unsatisfactory without retreatment. However, in patients without VR, the long-term outcome was good, indicating that a proportion of patients do not require infinite NUC treatment.
The limitation of this study was the relatively small sample size. Although we found that a CTLA4 (rs231775) and HLA-DPA1 (rs3077) host genotype might be associated with relapse, additional studies on immunological phenotypes are required to investigate T-cell exhaustion and recovery, which might play key roles in viral relapse. The optimal consolidation duration remains unclear from current guidelines [36] . A recent study suggested that a prolonged consolidation period can reduce the risk of relapse [8] . In our study, because of the relative homogeneity of the treatment and consolidation duration, verifying the treatment-related predictors for relapse is difficult.
In summary, our results show that despite 3 years of NUC therapy with a consolidation duration of >2 years, a substantial proportion of patients experience both VR and CR. TDF treatment discontinuation is associated with a significantly earlier relapse than is discontinuation of ETV therapy. In addition, the CTLA4 (rs231775) non-GG genotype predicts VR and CR, whereas HLA-DPA1 (rs3077) AA genotypes predict SCR. The EOT HBsAg level may enable identification of candidates who can discontinue NUC therapy with a low risk of relapse, and the HBV DNA level 1 month after therapy could serve as an early predictor of VR and CR after discontinuation of NUC therapy.
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